

L Number	Hits	Search Text	DB	Time stamp
1	173	corte.inv.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/08/17 14:42
2	2277	bart.inv.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/08/17 14:42
3	21	corte.inv. adj bart.inv.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/08/17 15:36
4	838	(544/321).CCLS.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/08/17 15:37
5	469	(514/272).CCLS.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/08/17 15:37

L Number	Hits	Search Text	DB	Time stamp
1	173	corte.inv.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/08/17 14:42
2	2277	bart.inv.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/08/17 14:42
3	21	corte.inv. adj bart.inv.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/08/17 15:36
4	838	(544/321).CCLS.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/08/17 15:37
5	469	(514/272).CCLS.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/08/17 15:37

V. Balasubramanian

Welcome to STN International! Enter x:x

LOGINID: ssspta1611bxv

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* Welcome to STN International \* \* \* \* \* \* \* \* \* \* \* \* \* \* \*

NEWS	1	Web Page URLs for STN Seminar Schedule - N. America
NEWS	2	"Ask CAS" for self-help around the clock
NEWS	3	May 12 EXTEND option available in structure searching
NEWS	4	May 12 Polymer links for the POLYLINK command completed in REGISTRY
NEWS	5	May 27 New UPM (Update Code Maximum) field for more efficient patent SDIs in CAplus
NEWS	6	May 27 CAplus super roles and document types searchable in REGISTRY
NEWS	7	Jun 28 Additional enzyme-catalyzed reactions added to CASREACT
NEWS	8	Jun 28 ANTE, AQUALINE, BIOENG, CIVILENG, ENVIROENG, MECHENG, and WATER from CSA now available on STN(R)
NEWS	9	Jul 12 BEILSTEIN enhanced with new display and select options, resulting in a closer connection to BABS
NEWS	10	Jul 30 BEILSTEIN on STN workshop to be held August 24 in conjunction with the 228th ACS National Meeting
NEWS	11	AUG 02 IFIPAT/IFIUDB/IFICDB reloaded with new search and display fields
NEWS	12	AUG 02 CAplus and CA patent records enhanced with European and Japan Patent Office Classifications
NEWS	13	AUG 02 STN User Update to be held August 22 in conjunction with the 228th ACS National Meeting
NEWS	14	AUG 02 The Analysis Edition of STN Express with Discover! (Version 7.01 for Windows) now available
NEWS	15	AUG 04 Pricing for the Save Answers for SciFinder Wizard within STN Express with Discover! will change September 1, 2004
NEWS EXPRESS		JULY 30 CURRENT WINDOWS VERSION IS V7.01, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 11 AUGUST 2004
NEWS HOURS		STN Operating Hours Plus Help Desk Availability
NEWS INTER		General Internet Information
NEWS LOGIN		Welcome Banner and News Items
NEWS PHONE		Direct Dial and Telecommunication Network Access to STN
NEWS WWW		CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

V. Balasubramanian

FILE 'HOME' ENTERED AT 14:20:42 ON 17 AUG 2004

=> file reg  
COST IN U.S. DOLLARS  
  
FULL ESTIMATED COST

SINCE FILE ENTRY	TOTAL SESSION
0.21	0.21

FILE 'REGISTRY' ENTERED AT 14:20:57 ON 17 AUG 2004  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 16 AUG 2004 HIGHEST RN 727651-15-2  
DICTIONARY FILE UPDATES: 16 AUG 2004 HIGHEST RN 727651-15-2

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:  
<http://www.cas.org/ONLINE/DBSS/registryss.html>

=> ....Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end

=>  
Uploading C:\STNEXP4\QUERIES\10634682.str

The diagram shows a chemical structure with various functional groups and substituents. A benzene ring on the left is substituted with a phenyl group at position 1 and a 4-(2-methoxyphenyl)pyrimidine group at position 4. A 4-phenylpyrimidine ring is connected via its nitrogen atom to the 2-position of the first pyrimidine ring. The 4-phenyl group of this second pyrimidine ring is further substituted with a phenyl group. A chain of three rings follows: a five-membered ring fused to a six-membered ring, which is fused to another six-membered ring. The atoms in these rings are numbered 1 through 17. The entire structure is labeled with 'CN 22' at the top right.

chain nodes :

7 9 21 22

ring nodes :

1 2 3 4 5 6 8 10 11 12 13 14 15 16 17 18 19 20

chain bonds :

3-9 5-7 7

ring bonds :

1-2    1-6    2-3    3-4

16-17 17-18 18-19 19-20  
exact/norm bonds :

3-9    5-7    7-8    9-1

normalized bonds :

1-2    1-6    2-3    3-4

16-17 17-18 18-19 19-20

10.1007/s00339-017-0907-0

10, 654, 002

V. Balasubramanian

isolated ring systems :  
containing 1 : 8 : 10 :

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:Atom 9:CLASS 10:Atom  
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom  
20:Atom 21:CLASS 22:CLASS 23:CLASS 24:CLASS

L1 STRUCTURE UPLOADED


=> que L1

L2 QUE L1

=> d l1

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss sam

SAMPLE SEARCH INITIATED 14:21:20 FILE 'REGISTRY'  
SAMPLE SCREEN SEARCH COMPLETED - 4 TO ITERATE

100.0% PROCESSED 4 ITERATIONS 3 ANSWERS  
SEARCH TIME: 00.00.01


FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*  
PROJECTED ITERATIONS: 4 TO 200  
PROJECTED ANSWERS: 3 TO 163

L3 3 SEA SSS SAM L1

=> d scan

V. Balasubramanian

L3 3 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN  
IN Benzonitrile, 3,5-dibromo-4-[2-[(4-cyanophenyl)amino]-5-fluoro-6-(hydroxymethyl)-4-pyrimidinyl]oxy]- (9CI)  
MF C19 H10 Br2 F N5 O2




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):2

V. Balasubramanian


L3 3 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN  
IN Benzonitrile, 4-[[5-bromo-2-[(4-cyanophenyl)amino]-4-pyrimidinyl]oxy]-3,5-  
dimethyl- (9CI)  
MF C20 H14 Br N5 O



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

V. Balasubramanian

L3 3 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN  
IN Acetamide, N-[5-bromo-4-(4-cyano-2,6-dimethylphenoxy)-2-pyrimidinyl]-N-(4-cyanophenyl)- (9CI)  
MF C22 H16 Br N5 O2



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

ALL ANSWERS HAVE BEEN SCANNED

V. Balasubramanian

=> s 11 sss ful  
FULL SEARCH INITIATED 14:21:41 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 79 TO ITERATE

100.0% PROCESSED 79 ITERATIONS 51 ANSWERS  
SEARCH TIME: 00.00.01

L4 51 SEA SSS FUL L1

=> file caplus  
COST IN U.S. DOLLARS SINCE FILE TOTAL  
FULL ESTIMATED COST ENTRY SESSION  
155.42 155.63

FILE 'CAPLUS' ENTERED AT 14:21:46 ON 17 AUG 2004  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 17 Aug 2004 VOL 141 ISS 8  
FILE LAST UPDATED: 16 Aug 2004 (20040816/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 14  
L5 23 L4

=> d 15 1-23 bib hitstr

V. Balasubramanian

L5 ANSWER 1 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN  
AN 2004:486399 CAPLUS  
DN 141:54353  
TI Pharmaceutical compositions comprising a surfactant and a physiologically tolerable water-soluble acid respectively base, and a basic respectively acidic drug compound, containing a pyrimidine unit, for treating HIV  
IN Vandecruys, Roger Petrus Gerebern  
PA Janssen Pharmaceutica N.V., Belg.  
SO PCT Int. Appl., 138 pp.  
CODEN: PIXXD2

DT Patent  
LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004050068	A1	20040617	WO 2002-EP13558	20021129
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	WO 2004050058	A2	20040617	WO 2003-EP50890	20031125
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRAI WO 2002-EP13558 A 20021129

IT 269055-15-4P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(anti-HIV agent; preparation of pyrimidine-based anti-HIV agents and their pharmaceutical compns.)

RN 269055-15-4 CAPLUS

CN Benzonitrile, 4-[(6-amino-5-bromo-2-[(4-cyanophenyl)amino]-4-pyrimidinyl)oxy]-3,5-dimethyl- (9CI) (CA INDEX NAME)

V. Balasubramanian




RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

V. Balasubramanian


L5 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN  
AN 2004:412943 CAPLUS  
DN 140:423711  
TI Preparation of 1,1-dioxido-4H-1,2,4-benzothiadiazines as hepatitis C polymerase inhibitors and anti-infective agents  
IN Pratt, John K.; Betebenner, David A.; Donner, Pamela L.; Green, Brian E.; Kempf, Dale J.; McDaniel, Keith F.; Maring, Clarence J.; Stoll, Vincent S.; Zhang, Rong  
PA Abbott Laboratories, USA  
SO PCT Int. Appl., 514 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004041818	A1	20040521	WO 2003-US34707	20031031
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2004097492	A1	20040520	US 2002-285714	20021101
	US 2004087577	A1	20040506	US 2003-410853	20030410
PRAI	US 2002-285714	A	20021101		
	US 2003-410853	A	20030410		
	US 2003-625121	A	20030723		
	US 2003-679881	A	20031006		
OS	MARPAT 140:423711				
IT	<b>269055-15-4, TMC-125</b>				
	RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (combination therapy; preparation of 1,1-dioxidothiadiazines as hepatitis C polymerase inhibitors and anti-infective agents)				
RN	269055-15-4 CAPLUS				
CN	Benzonitrile, 4-[[6-amino-5-bromo-2-[(4-cyanophenyl)amino]-4-pyrimidinyl]oxy]-3,5-dimethyl- (9CI) (CA INDEX NAME)				




V. Balasubramanian

L5 ANSWER 3 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN  
AN 2004:279153 CAPLUS  
DN 141:406  
TI Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (Etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants  
AU Das, Kalyan; Clark, Arthur D., Jr.; Lewi, Paul J.; Heeres, Jan; De Jonge, Marc R.; Koymans, Lucien M. H.; Vinkers, H. Maarten; Daeyaert, Frederik; Ludovici, Donald W.; Kukla, Michael J.; De Corte, Bart; Kavash, Robert W.; Ho, Chih Y.; Ye, Hong; Lichtenstein, Mark. A.; Andries, Koen; Pauwels, Rudi; De Bethune, Marie-Pierre; Boyer, Paul L.; Clark, Patrick; Hughes, Stephen H.; Janssen, Paul A. J.; Arnold, Eddy  
CS Center for Advanced Biotechnology and Medicine and Department of Chemistry and Chemical Biology, Rutgers University, Piscataway, NJ, 08854, USA  
SO Journal of Medicinal Chemistry (2004), 47(10), 2550-2560  
CODEN: JMCMAR; ISSN: 0022-2623  
PB American Chemical Society  
DT Journal  
LA English  
IT 269055-15-4, Etravirine 373686-05-6, R 185545  
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); BIOL (Biological study)  
(structure activity relationship of conformational and positional adaptability of non-nucleoside reverse transcriptase inhibitors against wild-type and drug-resistant HIV-1 variants)  
RN 269055-15-4 CAPLUS  
CN Benzonitrile, 4-[[6-amino-5-bromo-2-[(4-cyanophenyl)amino]-4-pyrimidinyl]oxy]-3,5-dimethyl- (9CI) (CA INDEX NAME)



RN 373686-05-6 CAPLUS  
CN Benzonitrile, 4-[[5-bromo-2-[(4-cyanophenyl)amino]-6-(hydroxymethyl)-4-pyrimidinyl]oxy]-3,5-dimethyl- (9CI) (CA INDEX NAME)

V. Balasubramanian




RE.CNT 52 THERE ARE 52 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

V. Balasubramanian

L5 ANSWER 4 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN  
AN 2004:120835 CAPLUS  
DN 140:163887  
TI preparation of 4,4-disubstituted-3,4-dihydro-2(1H)-quinazolinone derivatives as HIV reverse transcriptase inhibitors  
IN Corbett, Jeffrey  
PA Bristol-Myers Squibb Company, USA  
SO PCT Int. Appl., 50 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004013110	A1	20040212	WO 2003-US24006	20030731
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2004063734	A1	20040401	US 2003-632192	20030731
PRAI	US 2002-400409P	P	20020801		
OS	MARPAT	140:163887			
IT	<b>269055-15-4P</b> , TMC-125				
	RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(preparation of 4,4-disubstituted-3,4-dihydro-2(1H)-quinazolinone derivs. as HIV reverse transcriptase inhibitors)				
RN	269055-15-4	CAPLUS			
CN	Benzonitrile, 4-[[6-amino-5-bromo-2-[(4-cyanophenyl)amino]-4-pyrimidinyl]oxy]-3,5-dimethyl-	(9CI)	(CA INDEX NAME)		



V. Balasubramanian


L5 ANSWER 5 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN  
AN 2004:20432 CAPLUS  
DN 140:77032  
TI Preparation of 2,4-disubstituted pyridine N-oxides useful as HIV reverse transcriptase inhibitors  
IN Rodgers, James D.; Wang, Haisheng  
PA Bristol-Myers Squibb Company, USA  
SO PCT Int. Appl., 71 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004002410	A2	20040108	WO 2003-US19917	20030625
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2004019047	A1	20040129	US 2003-603431	20030625
PRAI	US 2002-392092P	P	20020627		
OS	MARPAT	140:77032			
IT	<b>269055-15-4</b> , TMC 125				
	RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (treatment in combination with; preparation of disubstituted pyridine N-oxides useful as HIV reverse transcriptase inhibitors)				
RN	269055-15-4	CAPLUS			
CN	Benzonitrile, 4-[[6-amino-5-bromo-2-[(4-cyanophenyl)amino]-4-pyrimidinyl]oxy]-3,5-dimethyl-	(9CI)	(CA INDEX NAME)		



V. Balasubramanian


L5 ANSWER 6 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN  
AN 2003:986852 CAPLUS  
DN 141:116472  
TI TMC125 exerts similar initial antiviral potency as a five-drug, triple class antiretroviral regimen  
AU Sankatsing, Sanjay U.; Weverling, Gerrit J.; Peeters, Monika; van't Klooster, Gerben A.; Gruzdev, Boris; Rakhmanova, Aza; Danner, Sven A.; Jurriaans, Suzanne; Prins, Jan M.; Lange, Joep M.  
CS Department of Internal Medicine, Division of Infectious Diseases, Tropical Medicine and AIDS, Univ. Amsterdam, Amsterdam, Neth.  
SO AIDS (London, United Kingdom) (2003), 17(18), 2623-2627  
CODEN: AIDSET; ISSN: 0269-9370  
PB Lippincott Williams & Wilkins  
DT Journal  
LA English  
IT 269055-15-4, TMC-125  
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(TMC125 exerts similar initial antiviral potency as a five-drug, triple class antiretroviral regimen)  
RN 269055-15-4 CAPLUS  
CN Benzonitrile, 4-[(6-amino-5-bromo-2-[(4-cyanophenyl)amino]-4-pyrimidinyl)oxy]-3,5-dimethyl- (9CI) (CA INDEX NAME)



RE.CNT 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

V. Balasubramanian

L5 ANSWER 7 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN  
AN 2003:986848 CAPLUS  
DN 141:116470  
TI An open-label assessment of TMC 125-a new, next-generation NNRTI, for 7 days in HIV-1 infected individuals with NNRTI resistance  
AU Gazzard, Brian G.; Pozniak, Anton L.; Rosenbaum, Willy; Yeni, G. Patrick; Staszewski, Schloomo; Arasteh, Keikawus; De Dier, Karin; Peeters, Monika; Woodfall, Brian; Stebbing, Justin; van't Klooster, Gerben A.  
CS Chelsea and Westminster Hospital, London, UK  
SO AIDS (London, United Kingdom) (2003), 17(18), F49-F54  
CODEN: AIDSET; ISSN: 0269-9370  
PB Lippincott Williams & Wilkins  
DT Journal  
LA English  
IT **269055-15-4**, TMC 125  
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(new generation NNRTI TMC-125 is well tolerated with significant antiviral activity in HIV-1 patient even in presence of mutations conferring high level of phenotypic resistance to efavirenz and nevirapine)  
RN 269055-15-4 CAPLUS  
CN Benzonitrile, 4-[(6-amino-5-bromo-2-[(4-cyanophenyl)amino]-4-pyrimidinyl)oxy]-3,5-dimethyl- (9CI) (CA INDEX NAME)



RE.CNT 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

V. Balasubramanian

L5 ANSWER 8 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN  
AN 2003:913004 CAPLUS  
DN 139:374987

TI Microbicidal pyrimidine or triazine compounds for preventing sexual HIV transmission

IN Van Roey, Jens Marcel; De Bethune, Marie-Pierre T. M. M. G.; Stoffels, Paul

PA Tibotec Pharmaceuticals Ltd., Ire.

SO PCT Int. Appl., 59 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003094920	A1	20031120	WO 2003-EP50158	20030513
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRAI EP 2002-76897 A 20020513


OS MARPAT 139:374987

IT 244767-99-5 244767-99-5D, N-oxide or quaternary amine

derivs. 269055-04-1 269055-04-1D, N-oxide or  
quaternary amine derivs. 269055-15-4 269055-15-4D,  
N-oxide or quaternary amine derivs. 269055-19-8  
269055-19-8D, N-oxide or quaternary amine derivs.  
RL: DEV (Device component use); PAC (Pharmacological activity); THU  
(Therapeutic use); BIOL (Biological study); USES (Uses)  
(pyrimidine and triazine compds. for preventing sexual HIV  
transmission)


RN 244767-99-5 CAPLUS

CN Benzonitrile, 4-[(2-[(4-cyanophenyl)amino]-4-pyrimidinyl]oxy]-3,5-dimethyl-  
(9CI) (CA INDEX NAME)




V. Balasubramanian


RN 244767-99-5 CAPLUS  
CN Benzonitrile, 4-[(2-[(4-cyanophenyl)amino]-4-pyrimidinyl]oxy)-3,5-dimethyl-  
(9CI) (CA INDEX NAME)



RN 269055-04-1 CAPLUS  
CN Benzonitrile, 4-[(5-bromo-2-[(4-cyanophenyl)amino]-4-pyrimidinyl]oxy)-3,5-dimethyl- (9CI) (CA INDEX NAME)




RN 269055-04-1 CAPLUS  
CN Benzonitrile, 4-[(5-bromo-2-[(4-cyanophenyl)amino]-4-pyrimidinyl]oxy)-3,5-dimethyl- (9CI) (CA INDEX NAME)




RN 269055-15-4 CAPLUS

CN Benzonitrile, 4-[[6-amino-5-bromo-2-[(4-cyanophenyl)amino]-4-pyrimidinyl]oxy]-3,5-dimethyl- (9CI) (CA INDEX NAME)



RN 269055-15-4 CAPLUS


CN Benzonitrile, 4-[[6-amino-5-bromo-2-[(4-cyanophenyl)amino]-4-pyrimidinyl]oxy]-3,5-dimethyl- (9CI) (CA INDEX NAME)



V. Balasubramanian


RN 269055-19-8 CAPLUS

CN Benzonitrile, 4-[[6-amino-5-chloro-2-[(4-cyanophenyl)amino]-4-pyrimidinyl]oxy]-3,5-dimethyl- (9CI) (CA INDEX NAME)



RN 269055-19-8 CAPLUS

CN Benzonitrile, 4-[[6-amino-5-chloro-2-[(4-cyanophenyl)amino]-4-pyrimidinyl]oxy]-3,5-dimethyl- (9CI) (CA INDEX NAME)



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

V. Balasubramanian

L5 ANSWER 9 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN  
AN 2003:892834 CAPLUS  
DN 139:365764  
TI Diblock copolymers for use in pharmaceutical dosage forms  
IN Arieen, Albertina Maria Eduarda; Brewster, Marcus Eli; Nathan, Aruna;  
Rosenblatt, Joel; Ould-Quali, Louisa Myriam; Preat, Veronique  
PA Janssen Pharmaceutica N.V., Belg.  
SO PCT Int. Appl., 46 pp.  
CODEN: PIXXD2

DT Patent  
LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003093344	A1	20031113	WO 2003-EP4368	20030424
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				


PRAI US 2002-377901P P 20020503

IT 269055-15-4, TMC 125

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(diblock copolymers for use in pharmaceutical dosage forms)

RN 269055-15-4 CAPLUS


CN Benzonitrile, 4-[[6-amino-5-bromo-2-[(4-cyanophenyl)amino]-4-pyrimidinyl]oxy]-3,5-dimethyl- (9CI) (CA INDEX NAME)



RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

V. Balasubramanian

L5 ANSWER 10 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN  
AN 2003:871684 CAPLUS  
DN 141:99044  
TI A randomized, double-blind, placebo-controlled trial of TMC125 as 7-day monotherapy in antiretroviral naive, HIV-1 infected subjects  
AU Gruzdev, Boris; Rakhamanova, Aza; Doubovskaya, Ekaterina; Yakovlev, Alexey; Peeters, Monika; Rinehart, Alex; De Dier, Karin; Baede-Van Dijk, Patricia; Parys, Wim; Van't Klooster, Gerben  
CS Infectious Diseases Hospital, Russian Federation, Neth.  
SO AIDS (London, United Kingdom) (2003), 17(17), 2487-2494  
CODEN: AIDSET; ISSN: 0269-9370  
PB Lippincott Williams & Wilkins  
DT Journal  
LA English  
IT **269055-15-4**, TMC125  
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(short-term TMC125 monotherapy was well tolerated with steady-state pharmacokinetics, decreased plasma HIV-1 RNA with remarkable viral decay rate and increased CD4 cell count in antiretroviral naive, HIV-1 infected patients)  
RN 269055-15-4 CAPLUS  
CN Benzonitrile, 4-[[6-amino-5-bromo-2-[(4-cyanophenyl)amino]-4-pyrimidinyl]oxy]-3,5-dimethyl- (9CI) (CA INDEX NAME)




RE.CNT 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

V. Balasubramanian

L5 ANSWER 11 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN  
AN 2003:591181 CAPLUS  
DN 139:149647  
TI Preparation of 5,10-dihydropyrimido[5,4-b]quinolin-4(3H)-ones as HIV reverse transcriptase inhibitors  
IN Tarby, Christine M.  
PA Bristol-Myers Squibb Company, USA  
SO PCT Int. Appl., 95 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003062238	A1	20030731	WO 2003-US1604	20030116
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003162800	A1	20030828	US 2003-346613	20030117
PRAI US 2002-349641P	P	20020118		
OS MARPAT 139:149647				
IT 269055-15-4, TMC 125				
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (combination therapy; preparation of pyrimido[5,4-b]quinolinones as HIV reverse transcriptase inhibitors)				
RN 269055-15-4 CAPLUS				
CN Benzonitrile, 4-[[6-amino-5-bromo-2-[(4-cyanophenyl)amino]-4-pyrimidinyl]oxy]-3,5-dimethyl- (9CI) (CA INDEX NAME)				



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

V. Balasubramanian


L5 ANSWER 12 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN  
AN 2003:316300 CAPLUS  
DN 139:46478  
TI Validation of a model for the complex of HIV-1 reverse transcriptase with nonnucleoside inhibitor TMC125  
AU Udier-Blagovic, Marina; Tirado-Rives, Julian; Jorgensen, William L.  
CS Department of Chemistry, Yale University, New Haven, CT, 06520-8107, USA  
SO Journal of the American Chemical Society (2003), 125(20), 6016-6017  
CODEN: JACSAT; ISSN: 0002-7863  
PB American Chemical Society  
DT Journal  
LA English  
IT **269055-15-4**, TMC 125  
RL: PAC (Pharmacological activity); PRP (Properties); BIOL (Biological study)  
(validation of a model for the complex of HIV-1 reverse transcriptase with nonnucleoside inhibitor TMC125)  
RN 269055-15-4 CAPLUS  
CN Benzonitrile, 4-[[6-amino-5-bromo-2-[(4-cyanophenyl)amino]-4-pyrimidinyl]oxy]-3,5-dimethyl- (9CI) (CA INDEX NAME)



RE.CNT 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

V. Balasubramanian

L5 ANSWER 13 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN  
AN 2003:302361 CAPLUS  
DN 139:345031  
TI New antiretroviral drugs  
AU Gulick, R. M.  
CS Cornell HIV Clinical Trials Unit, Division of International Medicine and Infectious Diseases, Weill Medical College of Cornell University, New York, NY, 10024, USA  
SO Clinical Microbiology and Infection (2003), 9(3), 186-193  
CODEN: CMINFM; ISSN: 1198-743X  
PB Blackwell Publishing Ltd.  
DT Journal; General Review  
LA English  
IT **269055-15-4**, TMC 125  
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(new antiretroviral drugs)  
RN 269055-15-4 CAPLUS  
CN Benzonitrile, 4-[[6-amino-5-bromo-2-[(4-cyanophenyl)amino]-4-pyrimidinyl]oxy]-3,5-dimethyl- (9CI) (CA INDEX NAME)




RE.CNT 62 THERE ARE 62 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

V. Balasubramanian

L5 ANSWER 14 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN  
AN 2002:695941 CAPLUS  
DN 137:232453  
TI Preparation of substituted benzophenones as inhibitors of reverse transcriptase  
IN Chan, Joseph Howing  
PA Smithkline Beecham Corporation, USA  
SO PCT Int. Appl., 163 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002070470	A2	20020912	WO 2002-US6037	20020228
	WO 2002070470	A3	20030306		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1363877	A2	20031126	EP 2002-723265	20020228
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	BR 2002007752	A	20040323	BR 2002-7752	20020228
	NZ 527864	A	20040528	NZ 2002-527864	20020228
	NO 2003003857	A	20031027	NO 2003-3857	20030901
	US 2004122064	A1	20040624	US 2004-469104	20040205
PRAI	US 2001-272953P	P	20010302		
	WO 2002-US6037	W	20020228		
OS	MARPAT 137:232453				
IT	<b>269055-15-4</b> , TMC-125				
	RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (combination pharmaceutical; preparation of substituted benzophenones as inhibitors of reverse transcriptase)				
RN	269055-15-4 CAPLUS				
CN	Benzonitrile, 4-[[6-amino-5-bromo-2-[(4-cyanophenyl)amino]-4-pyrimidinyl]oxy]-3,5-dimethyl- (9CI) (CA INDEX NAME)				



V. Balasubramanian

L5 ANSWER 15 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN  
 AN 2002:90044 CAPLUS

DN 136:151150

TI Tricyclic 2-pyridone compounds useful as HIV reverse transcriptase inhibitors and their use as antiviral agents in the treatment of HIV infection

IN Rodgers, James D.; Wang, Haisheng; Patel, Mona; Arvanitis, Argyrios; Cocuzza, Anthony J.

PA Dupont Pharmaceuticals Company, USA

SO PCT Int. Appl., 189 pp.


CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002008226	A2	20020131	WO 2001-US22827	20010720
	WO 2002008226	A3	20020620		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2002107261	A1	20020808	US 2001-908995	20010719
	US 6596729	B2	20030722		
	EP 1303515	A2	20030423	EP 2001-959047	20010720
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	SI 21139	C	20030831	SI 2001-20050	20010720
	BG 107439	A	20030930	BG 2003-107439	20030106
	NO 2003000248	A	20030317	NO 2003-248	20030117
	US 2004023955	A1	20040205	US 2003-457902	20030610
PRAI	US 2000-219532P	P	20000720		
	US 2001-284856P	P	20010419		
	US 2001-908995	A3	20010719		
	WO 2001-US22827	W	20010720		
OS	MARPAT 136:151150				
IT	<b>269055-15-4</b>				
	RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (pharmaceutical compns. also containing; preparation of tricyclic 2-pyridone compds. as HIV reverse transcriptase inhibitors)				
RN	269055-15-4 CAPLUS				
CN	Benzonitrile, 4-[[6-amino-5-bromo-2-[(4-cyanophenyl)amino]-4-pyrimidinyl]oxy]-3,5-dimethyl- (9CI) (CA INDEX NAME)				




V. Balasubramanian

L5 ANSWER 16 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN  
AN 2001:833290 CAPLUS  
DN 135:371765  
TI Preparation of substituted amino pyrimidines and triazines as HIV replication inhibitors  
IN Kukla, Michael Joseph; Ludovici, Donald William; Kavash, Robert W.; De Corte, Bart Lieven Daniel; Heeres, Jan; Janssen, Paul Adriaan Jan; Koymans, Lucien Maria Henricus; De Jonge, Marc Rene; Van Aken Koen, Jeanne Alfons; Krief, Alain; Leenders, Ruben Gerardus George  
PA Janssen Pharmaceutica N.V., Belg.  
SO PCT Int. Appl., 80 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001085700	A2	20011115	WO 2001-EP4991	20010503
	WO 2001085700	A3	20020207		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	EP 1282606	A2	20030212	EP 2001-929616	20010503
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2003535828	T2	20031202	JP 2001-582301	20010503
	US 2003171374	A1	20030911	US 2002-275931	20021108
PRAI	US 2000-202472B	P	20000508		
	WO 2001-EP4991	W	20010503		
OS	MARPAT 135:371765				
IT	<b>373684-83-4P 373688-31-4P</b>				
	RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)				
	(preparation of substituted amino pyrimidines and triazines as HIV replication inhibitors)				
RN	373684-83-4 CAPLUS				
CN	Benzonitrile, 4-[[2-[(4-cyanophenyl)amino]-6-(methoxymethyl)-4-pyrimidinyl]oxy]-3,5-dimethyl- (9CI) (CA INDEX NAME)				



RN 373688-31-4 CAPLUS  
CN Benzonitrile, 3,5-dibromo-4-[(2-[(4-cyanophenyl)amino]-6-(hydroxymethyl)-4-pyrimidinyl]oxy]- (9CI) (CA INDEX NAME)




IT 373684-45-8P 373686-00-1P 373686-05-6P  
373686-12-5P 373686-18-1P 373686-25-0P  
373686-31-8P 373688-25-6P 373689-13-5P  
373689-18-0P  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of substituted amino pyrimidines and triazines as HIV replication inhibitors)  
RN 373684-45-8 CAPLUS  
CN 4-Pyrimidinecarboxylic acid, 6-(4-cyano-2,6-dimethylphenoxy)-2-[(4-cyanophenyl)amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 373686-00-1 CAPLUS

CN Benzonitrile, 4-[(5-bromo-2-[(4-cyanophenyl)amino]-6-(methoxymethyl)-4-pyrimidinyl]oxy]-3,5-dimethyl- (9CI) (CA INDEX NAME)



RN 373686-05-6 CAPLUS


CN Benzonitrile, 4-[(5-bromo-2-[(4-cyanophenyl)amino]-6-(hydroxymethyl)-4-pyrimidinyl]oxy]-3,5-dimethyl- (9CI) (CA INDEX NAME)



V. Balasubramanian


RN 373686-12-5 CAPLUS

CN Benzonitrile, 4-[[5-bromo-6-(chloromethyl)-2-[(4-cyanophenyl)amino]-4-pyrimidinyl]oxy]-3,5-dimethyl- (9CI) (CA INDEX NAME)




RN 373686-18-1 CAPLUS

CN Benzonitrile, 4-[[5-bromo-2-[(4-cyanophenyl)amino]-6-[(methylamino)methyl]-4-pyrimidinyl]oxy]-3,5-dimethyl- (9CI) (CA INDEX NAME)




RN 373686-25-0 CAPLUS

CN Benzonitrile, 3,5-dibromo-4-[[2-[(4-cyanophenyl)amino]-5-fluoro-6-(hydroxymethyl)-4-pyrimidinyl]oxy]- (9CI) (CA INDEX NAME)




RN 373686-31-8 CAPLUS

CN Benzonitrile, 3,5-dibromo-4-[(5-bromo-2-[(4-cyanophenyl)amino]-6-hydroxymethyl)-4-pyrimidinyl]oxy]- (9CI) (CA INDEX NAME)




RN 373688-25-6 CAPLUS

CN Benzonitrile, 3,5-dibromo-4-[(2-[(4-cyanophenyl)amino]-6-(methoxymethyl)-4-pyrimidinyl]oxy]- (9CI) (CA INDEX NAME)




V. Balasubramanian

RN 373689-13-5 CAPLUS  
CN Benzonitrile, 4-[[5-bromo-2-[(4-cyanophenyl)amino]-6-[(dimethylamino)methyl]-4-pyrimidinyl]oxy]-3,5-dimethyl- (9CI) (CA INDEX NAME)





RN 373689-18-0 CAPLUS  
CN Benzonitrile, 4-[[5-bromo-2-[(4-cyanophenyl)amino]-6-[(ethylamino)methyl]-4-pyrimidinyl]oxy]-3,5-dimethyl- (9CI) (CA INDEX NAME)



V. Balasubramanian



L5 ANSWER 17 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN  
 AN 2001:833289 CAPLUS  
 DN 135:371756  
 TI Preparation of prodrugs of HIV replication inhibiting pyrimidines  
 IN Kukla, Michael Joseph; Ludovici, Donald William; Kavash, Robert W.; De  
     Corte, Bart Lieven Daniel; Heeres, Jan; Janssen, Paul Adriaan Jan;  
     Koymans, Lucien Maria Henricus; De Jonge, Marc Rene; Van Aken Koen, Jeanne  
     Alfons; Krief, Alain  
 PA Janssen Pharmaceutica N.V., Belg.  
 SO PCT Int. Appl., 55 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001085699	A2	20011115	WO 2001-EP4990	20010503
	WO 2001085699	A3	20020228		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BE, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 2001060277	A5	20011120	AU 2001-60277	20010503
	EP 1282607	A2	20030212	EP 2001-933925	20010503
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2003532713	T2	20031105	JP 2001-582300	20010503
	US 2003186990	A1	20031002	US 2002-275333	20021107
PRAI	US 2000-202471P	P	20000508		
	WO 2001-EP4990	W	20010503		
OS	MARPAT	135:371756			
IT	<b>373791-74-3P 373791-80-1P 373791-86-7P</b> <b>373791-91-4P 373791-97-0P 373792-02-0P</b> <b>373792-10-0P 373792-16-6P 373792-24-6P</b> <b>373792-32-6P 373792-37-1P 373792-43-9P</b> <b>373792-48-4P 373792-54-2P</b>				
	RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of prodrugs of HIV replication inhibiting pyrimidines)				
RN	373791-74-3 CAPLUS				
CN	Benzonitrile, 4-[[5-bromo-2-[(4-cyanophenyl)(ethoxymethyl)amino]-4- pyrimidinyl]oxy]-3,5-dimethyl- (9CI) (CA INDEX NAME)				




RN 373791-80-1 CAPLUS

CN Benzonitrile, 4-[(5-bromo-2-[(cyanomethyl)(4-cyanophenyl)amino]-4-pyrimidinyl)oxy]-3,5-dimethyl- (9CI) (CA INDEX NAME)




RN 373791-86-7 CAPLUS

CN Benzonitrile, 4-[(5-bromo-2-[(4-cyanophenyl)[(2-hydroxyethoxy)methyl]amino]-4-pyrimidinyl)oxy]-3,5-dimethyl- (9CI) (CA INDEX NAME)




RN 373791-91-4 CAPLUS


CN Butanoic acid, 4-[(5-bromo-4-(4-cyano-2,6-dimethylphenoxy)-2-pyrimidinyl)(4-cyanophenyl)amino]-4-oxo-, 2-(4-morpholinyl)ethyl ester (9CI) (CA INDEX NAME)




RN 373791-97-0 CAPLUS  
CN Benzonitrile, 4-[{2-[{2-(benzoyloxy)ethoxy]methyl}(4-cyanophenyl)amino]-5-bromo-4-pyrimidinyl]oxy]-3,5-dimethyl- (9CI) (CA INDEX NAME)




RN 373792-02-0 CAPLUS  
CN Benzonitrile, 4-[{5-bromo-2-[{(4-cyanophenyl)[(octyloxy)methyl]amino}-4-pyrimidinyl]oxy}-3,5-dimethyl- (9CI) (CA INDEX NAME)




RN 373792-10-0 CAPLUS  
CN Benzonitrile, 4-[{5-bromo-2-[{(4-cyanophenyl)[(2-methoxyethoxy)methyl]amino}-4-pyrimidinyl]oxy}-3,5-dimethyl- (9CI) (CA INDEX NAME)




RN 373792-16-6 CAPLUS  
 CN 1H-Imidazole-4-sulfonamide, N-[5-bromo-4-(4-cyano-2,6-dimethylphenoxy)-2-pyrimidinyl]-N-(4-cyanophenyl)-1-methyl- (9CI) (CA INDEX NAME)



RN 373792-24-6 CAPLUS  
 CN Methanesulfonamide, N-[5-bromo-4-(4-cyano-2,6-dimethylphenoxy)-2-pyrimidinyl]-N-(4-cyanophenyl)- (9CI) (CA INDEX NAME)




RN 373792-32-6 CAPLUS  
 CN Benzenesulfonamide, N-[5-bromo-4-(4-cyano-2,6-dimethylphenoxy)-2-pyrimidinyl]-N-(4-cyanophenyl)- (9CI) (CA INDEX NAME)




V. Balasubramanian


RN 373792-37-1 CAPLUS  
CN Benzenesulfonamide, N-[5-bromo-4-(4-cyano-2,6-dimethylphenoxy)-2-pyrimidinyl]-N-(4-cyanophenyl)-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 373792-43-9 CAPLUS  
CN Octanamide, N-[5-bromo-4-(4-cyano-2,6-dimethylphenoxy)-2-pyrimidinyl]-N-(4-cyanophenyl)- (9CI) (CA INDEX NAME)



RN 373792-48-4 CAPLUS  
CN Butanoic acid, 4-[[5-bromo-4-(4-cyano-2,6-dimethylphenoxy)-2-pyrimidinyl](4-cyanophenyl)amino]-4-oxo-, 2-(dimethylamino)ethyl ester (9CI) (CA INDEX NAME)



RN 373792-54-2 CAPLUS  
CN Butanoic acid, 4-[[5-bromo-4-(4-cyano-2,6-dimethylphenoxy)-2-pyrimidinyl](4-cyanophenyl)amino]-4-oxo-, 2-[[2-(dimethylamino)ethyl]methylamino]ethyl ester (9CI) (CA INDEX NAME)




IT 269055-76-7

RL: RCT (Reactant); RACT (Reactant or reagent)  
(preparation of prodrugs of HIV replication inhibiting pyrimidines)

RN 269055-76-7 CAPLUS

CN Benzonitrile, 4-[[5-bromo-6-chloro-2-[(4-cyanophenyl)amino]-4-pyrimidinyl]oxy]-3,5-dimethyl- (9CI) (CA INDEX NAME)



IT 269055-04-1P 269055-15-4P 269055-19-8P

269055-42-7P 269055-44-9P 269055-48-3P


269055-49-4P 269055-50-7P 269055-51-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)


(preparation of prodrugs of HIV replication inhibiting pyrimidines)

RN 269055-04-1 CAPLUS


CN Benzonitrile, 4-[[5-bromo-2-[(4-cyanophenyl)amino]-4-pyrimidinyl]oxy]-3,5-dimethyl- (9CI) (CA INDEX NAME)



RN 269055-15-4 CAPLUS  
CN Benzonitrile, 4-[[6-amino-5-bromo-2-[(4-cyanophenyl)amino]-4-pyrimidinyl]oxy]-3,5-dimethyl- (9CI) (CA INDEX NAME)




RN 269055-19-8 CAPLUS  
CN Benzonitrile, 4-[[6-amino-5-chloro-2-[(4-cyanophenyl)amino]-4-pyrimidinyl]oxy]-3,5-dimethyl- (9CI) (CA INDEX NAME)




V. Balasubramanian


RN 269055-42-7 CAPLUS  
CN Benzonitrile, 4-[[2-[(4-cyanophenyl)amino]-5-nitro-4-pyrimidinyl]oxy]-3,5-dimethyl- (9CI) (CA INDEX NAME)



RN 269055-44-9 CAPLUS  
CN Benzonitrile, 4-[[5-bromo-2-[(4-cyanophenyl)amino]-6-methyl-4-pyrimidinyl]oxy]-3,5-dimethyl- (9CI) (CA INDEX NAME)




RN 269055-48-3 CAPLUS  
CN Benzonitrile, 4-[[5-bromo-2-[(4-cyanophenyl)amino]-6-[[2-(1-pyrrolidinyl)ethyl]amino]-4-pyrimidinyl]oxy]-3,5-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 269055-49-4 CAPLUS

CN Benzonitrile, 4-[[5-bromo-2-[(4-cyanophenyl)amino]-6-(methoxyamino)-4-pyrimidinyl]oxy]-3,5-dimethyl- (9CI) (CA INDEX NAME)




RN 269055-50-7 CAPLUS

CN Acetamide, N-[4-(4-cyano-2,6-dimethylphenoxy)-2-[(4-cyanophenyl)amino]-5-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 269055-51-8 CAPLUS

CN Benzonitrile, 4-[(5-amino-2-[(4-cyanophenyl)amino]-4-pyrimidinyl]oxy]-3,5-dimethyl- (9CI) (CA INDEX NAME)




V. Balasubramanian

L5 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN  
AN 2001:628977 CAPLUS  
DN 135:371702  
TI Evolution of anti-HIV drug candidates. Part 3: diarylpyrimidine (DAPY) analogues  
AU Ludovici, D. W.; De Corte, B. L.; Kukla, M. J.; Ye, H.; Ho, C. Y.; Lichtenstein, M. A.; Kavash, R. W.; Andries, K.; de Bethune, M.-P.; Azijn, H.; Pauwels, R.; Lewi, P. J.; Heeres, J.; Koymans, L. M. H.; de Jonge, M. R.; Van Aken, K. J. A.; Daeyaert, F. F. D.; Das, K.; Arnold, E.; Janssen, P. A. J.  
CS Janssen Research Foundation, Spring House, PA, 19477, USA  
SO Bioorganic & Medicinal Chemistry Letters (2001), 11(17), 2235-2239  
CODEN: BMCLE8; ISSN: 0960-894X  
PB Elsevier Science Ltd.  
DT Journal  
LA English  
IT 244767-99-5P 269055-04-1P 269055-05-2P  
269055-15-4P 269055-42-7P 269055-50-7P  
269055-51-8P  
RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation) (synthesis and activity of diarylpyrimidines as non-nucleoside reverse transcriptase inhibitors)  
RN 244767-99-5 CAPLUS  
CN Benzonitrile, 4-[[2-[(4-cyanophenyl)amino]-4-pyrimidinyl]oxy]-3,5-dimethyl- (9CI) (CA INDEX NAME)




RN 269055-04-1 CAPLUS  
CN Benzonitrile, 4-[[5-bromo-2-[(4-cyanophenyl)amino]-4-pyrimidinyl]oxy]-3,5-dimethyl- (9CI) (CA INDEX NAME)




RN 269055-05-2 CAPLUS

CN Benzonitrile, 4-[(5-chloro-2-[(4-cyanophenyl)amino]-4-pyrimidinyl)oxy]-3,5-dimethyl- (9CI) (CA INDEX NAME)



RN 269055-15-4 CAPLUS


CN Benzonitrile, 4-[(6-amino-5-bromo-2-[(4-cyanophenyl)amino]-4-pyrimidinyl)oxy]-3,5-dimethyl- (9CI) (CA INDEX NAME)



V. Balasubramanian


RN 269055-42-7 CAPLUS

CN Benzonitrile, 4-[[2-[(4-cyanophenyl)amino]-5-nitro-4-pyrimidinyl]oxy]-3,5-dimethyl- (9CI) (CA INDEX NAME)



RN 269055-50-7 CAPLUS


CN Acetamide, N-[4-(4-cyano-2,6-dimethylphenoxy)-2-[(4-cyanophenyl)amino]-5-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 269055-51-8 CAPLUS

CN Benzonitrile, 4-[[5-amino-2-[(4-cyanophenyl)amino]-4-pyrimidinyl]oxy]-3,5-dimethyl- (9CI) (CA INDEX NAME)

V. Balasubramanian




RE.CNT 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT


V. Balasubramanian

L5 ANSWER 19 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN  
AN 2001:247156 CAPLUS  
DN 134:280865  
TI Preparation of azinylaminobenzonitriles and related compounds as virucides.  
IN Verreck, Geert; Baert, Lieven  
PA Janssen Pharmaceutica N.V., Belg.  
SO PCT Int. Appl., 89 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001022938	A1	20010405	WO 2000-EP8522	20000831
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	BR 2000014271	A	20020521	BR 2000-14271	20000831
	EP 1225874	A1	20020731	EP 2000-964080	20000831
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
	JP 2003510264	T2	20030318	JP 2001-526150	20000831
	EE 200200151	A	20030415	EE 2002-151	20000831
	NZ 517025	A	20030725	NZ 2000-517025	20000831
	TR 200200763	T2	20030922	TR 2002-200200763	20000831
	BG 106521	A	20021229	BG 2002-106521	20020314
	ZA 2002002289	A	20030620	ZA 2002-2289	20020320
	NO 2002001443	A	20020322	NO 2002-1443	20020322
PRAI	EP 1999-203128	A	19990924		
	WO 2000-EP8522	W	20000831		
OS	MARPAT	134:280865			
IT	<b>269055-42-7P 269055-51-8P</b>				
	RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)				
	(preparation of azinylaminobenzonitriles and related compds. as virucides)				
RN	269055-42-7	CAPLUS			
CN	Benzonitrile, 4-[[2-[(4-cyanophenyl)amino]-5-nitro-4-pyrimidinyl]oxy]-3,5-dimethyl-	(9CI)	(CA INDEX NAME)		




RN 269055-51-8 CAPLUS  
CN Benzonitrile, 4-[(5-amino-2-[(4-cyanophenyl)amino]-4-pyrimidinyl)oxy]-3,5-dimethyl- (9CI) (CA INDEX NAME)




IT 269055-04-1P 269055-05-2P 269055-14-3P  
269055-15-4P 269055-18-7P 269055-19-8P  
269055-26-7P 269055-28-9P 269055-32-5P  
269055-44-9P 269055-48-3P 269055-49-4P  
269055-50-7P 269055-58-5P 269055-59-6P  
269055-60-9P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of azinylaminobenzonitriles and related compds. as virucides)


RN 269055-04-1 CAPLUS  
CN Benzonitrile, 4-[(5-bromo-2-[(4-cyanophenyl)amino]-4-pyrimidinyl)oxy]-3,5-dimethyl- (9CI) (CA INDEX NAME)



RN 269055-05-2 CAPLUS  
CN Benzonitrile, 4-[[5-chloro-2-[(4-cyanophenyl)amino]-4-pyrimidinyl]oxy]-3,5-dimethyl- (9CI) (CA INDEX NAME)




RN 269055-14-3 CAPLUS  
CN Benzonitrile, 4-[[5-bromo-2-[(4-cyanophenyl)amino]-6-(methylamino)-4-pyrimidinyl]oxy]-3,5-dimethyl- (9CI) (CA INDEX NAME)



V. Balasubramanian


RN 269055-15-4 CAPLUS

CN Benzonitrile, 4-[[6-amino-5-bromo-2-[(4-cyanophenyl)amino]-4-pyrimidinyl]oxy]-3,5-dimethyl- (9CI) (CA INDEX NAME)




RN 269055-18-7 CAPLUS

CN Benzonitrile, 4-[[5-bromo-2-[(4-cyanophenyl)amino]-6-(ethylamino)-4-pyrimidinyl]oxy]-3,5-dimethyl- (9CI) (CA INDEX NAME)




RN 269055-19-8 CAPLUS

CN Benzonitrile, 4-[[6-amino-5-chloro-2-[(4-cyanophenyl)amino]-4-pyrimidinyl]oxy]-3,5-dimethyl- (9CI) (CA INDEX NAME)




RN 269055-26-7 CAPLUS

CN Benzonitrile, 4-[(5,6-dichloro-2-[(4-cyanophenyl)amino]-4-pyrimidinyl)oxy]-3,5-dimethyl- (9CI) (CA INDEX NAME)




RN 269055-28-9 CAPLUS


CN Benzonitrile, 4-[(6-bromo-5-chloro-2-[(4-cyanophenyl)amino]-4-pyrimidinyl)oxy]-3,5-dimethyl- (9CI) (CA INDEX NAME)




RN 269055-32-5 CAPLUS  
CN Acetamide, N-[5-bromo-4-(4-cyano-2,6-dimethylphenoxy)-2-pyrimidinyl]-N-(4-cyanophenyl)- (9CI) (CA INDEX NAME)



RN 269055-44-9 CAPLUS  
CN Benzonitrile, 4-[[5-bromo-2-[(4-cyanophenyl)amino]-6-methyl-4-pyrimidinyl]oxy]-3,5-dimethyl- (9CI) (CA INDEX NAME)




RN 269055-48-3 CAPLUS  
CN Benzonitrile, 4-[[5-bromo-2-[(4-cyanophenyl)amino]-6-[[2-(1-pyrrolidinyl)ethyl]amino]-4-pyrimidinyl]oxy]-3,5-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 269055-49-4 CAPLUS

CN Benzonitrile, 4-[(5-bromo-2-[(4-cyanophenyl)amino]-6-(methoxyamino)-4-pyrimidinyl)oxy]-3,5-dimethyl- (9CI) (CA INDEX NAME)




RN 269055-50-7 CAPLUS

CN Acetamide, N-[4-(4-cyano-2,6-dimethylphenoxy)-2-[(4-cyanophenyl)amino]-5-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 269055-58-5 CAPLUS

CN Glycine, N-[5-bromo-4-(4-cyano-2,6-dimethylphenoxy)-2-pyrimidinyl]-N-(4-cyanophenyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 269055-59-6 CAPLUS

CN Formamide, N-[5-bromo-4-(4-cyano-2,6-dimethylphenoxy)-2-pyrimidinyl]-N-(4-cyanophenyl)- (9CI) (CA INDEX NAME)



RN 269055-60-9 CAPLUS

CN Carbamic acid, [5-bromo-4-(4-cyano-2,6-dimethylphenoxy)-2-pyrimidinyl](4-cyanophenyl)-, ethyl ester (9CI) (CA INDEX NAME)




IT 269055-76-7

RL: RCT (Reactant); RACT (Reactant or reagent)  
(preparation of azinylaminobenzonitriles and related compds. as virucides)

RN 269055-76-7 CAPLUS

CN Benzonitrile, 4-[[5-bromo-6-chloro-2-[(4-cyanophenyl)amino]-4-pyrimidinyl]oxy]-3,5-dimethyl- (9CI) (CA INDEX NAME)



RE.CNT 5

THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

V. Balasubramanian

L5 ANSWER 20 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN  
AN 2001:225202 CAPLUS

DN 134:256875

TI Controlled-release microparticle formulation for antiviral drugs

IN Hantke, Thomas; Rehbock, Bettina; Rosenberg, Joerg; Breitenbach, Joerg

PA Knoll A.-G. Chemische Fabriken, Germany

SO Ger. Offen., 16 pp.


CODEN: GWXXBX

DT Patent

LA German


FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 19945982	A1	20010329	DE 1999-19945982	19990924
	WO 2001023362	A2	20010405	WO 2000-EP9149	20000919
	WO 2001023362	A3	20011206		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	EP 1214300	A2	20020619	EP 2000-964201	20000919
	EP 1214300	B1	20030903		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
	JP 2003518012	T2	20030603	JP 2001-526516	20000919
	AT 248822	E	20030915	AT 2000-964201	20000919
	NO 2002001409	A	20020321	NO 2002-1409	20020321
PRAI	DE 1999-19945982	A	19990924		
	WO 2000-EP9149	W	20000919		
IT	<b>269055-04-1 269055-15-4 269055-19-8</b>				
	RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses) (controlled-release microparticle formulation for antiviral drugs)				
RN	269055-04-1	CAPLUS			
CN	Benzonitrile, 4-[(5-bromo-2-[(4-cyanophenyl)amino]-4-pyrimidinyl]oxy]-3,5-dimethyl- (9CI) (CA INDEX NAME)				




RN 269055-15-4 CAPLUS

CN Benzonitrile, 4-[(6-amino-5-bromo-2-[(4-cyanophenyl)amino]-4-pyrimidinyl]oxy]-3,5-dimethyl- (9CI) (CA INDEX NAME)



RN 269055-19-8 CAPLUS

CN Benzonitrile, 4-[(6-amino-5-chloro-2-[(4-cyanophenyl)amino]-4-pyrimidinyl)oxy]-3,5-dimethyl- (9CI) (CA INDEX NAME)



V. Balasubramanian

L5 ANSWER 21 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN  
AN 2000:335393 CAPLUS  
DN 132:347578  
TI Preparation of arylaminopyrimidines as inhibitors of HIV replication.  
IN De Corte, Bart; De Jonge, Marc Rene; Heeres, Jan; Ho, Chih Yung; Janssen, Paul Adriaan Jan; Kavash, Robert W.; Koymans, Lucien Maria Henricus; Kukla, Michael Joseph; Ludovici, Donald William; Van Aken, Koen Jeanne Alfons  
PA Janssen Pharmaceutica N.V., Belg.; et al.  
SO PCT Int. Appl., 49 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000027825	A1	20000518	WO 1999-EP7417	19990924
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 9962008	A1	20000529	AU 1999-62008	19990924
	AU 762523	B2	20030626		
	BR 9915552	A	20010814	BR 1999-15552	19990924
	TR 200101306	T2	20011022	TR 2001-200101306	19990924
	EE 200100252	A	20021015	EE 2001-252	19990924
	NZ 511116	A	20030829	NZ 1999-511116	19990924
	EP 1002795	A1	20000524	EP 1999-203590	19991101
	EP 1002795	B1	20030305		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	EP 1270560	A1	20030102	EP 2002-18455	19991101
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
	AT 233740	E	20030315	AT 1999-203590	19991101
	US 2003114472	A1	20030619	US 1999-430966	19991101
	PT 1002795	T	20030731	PT 1999-203590	19991101
	ES 2193664	T3	20031101	ES 1999-203590	19991101
	HK 1025330	A1	20030613	HK 2000-104633	20000726
	HR 2001000161	A1	20020228	HR 2001-161	20010307
	NO 2001001696	A	20010404	NO 2001-1696	20010404
	BG 105418	A	20011130	BG 2001-105418	20010406
	ZA 2001003769	A	20020812	ZA 2001-3769	20010509
	US 2004039005	A1	20040226	US 2003-634682	20030805
PRAI	US 1998-107792P	P	19981110		
	US 1999-143962P	P	19990715		
	US 1998-107792	P	19981110		
	US 1999-143962	P	19990715		
	WO 1999-EP7417	W	19990924		
	EP 1999-203590	A3	19991101		
	US 1999-430966	A1	19991101		
OS	MARPAT 132:347578				
IT	269055-42-7P 269055-51-8P				


V. Balasubramanian

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of arylaminopyrimidines as inhibitors of HIV replication)


RN 269055-42-7 CAPLUS

CN Benzonitrile, 4-[[2-[(4-cyanophenyl)amino]-5-nitro-4-pyrimidinyl]oxy]-3,5-dimethyl- (9CI) (CA INDEX NAME)



RN 269055-51-8 CAPLUS

CN Benzonitrile, 4-[[5-amino-2-[(4-cyanophenyl)amino]-4-pyrimidinyl]oxy]-3,5-dimethyl- (9CI) (CA INDEX NAME)



IT 269055-04-1P 269055-05-2P 269055-14-3P  
269055-15-4P 269055-18-7P 269055-19-8P  
269055-26-7P 269055-28-9P 269055-32-5P  
269055-44-9P 269055-48-3P 269055-49-4P  
269055-50-7P 269055-58-5P 269055-59-6P  
269055-60-9P 269055-61-0P 269055-62-1P  
269055-63-2P 269055-78-9P 269055-79-0P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of arylaminopyrimidines as inhibitors of HIV replication)

V. Balasubramanian


RN 269055-04-1 CAPLUS

CN Benzonitrile, 4-[(5-bromo-2-[(4-cyanophenyl)amino]-4-pyrimidinyl]oxy]-3,5-dimethyl- (9CI) (CA INDEX NAME)




RN 269055-05-2 CAPLUS

CN Benzonitrile, 4-[(5-chloro-2-[(4-cyanophenyl)amino]-4-pyrimidinyl]oxy]-3,5-dimethyl- (9CI) (CA INDEX NAME)




RN 269055-14-3 CAPLUS

CN Benzonitrile, 4-[(5-bromo-2-[(4-cyanophenyl)amino]-6-(methylamino)-4-pyrimidinyl]oxy]-3,5-dimethyl- (9CI) (CA INDEX NAME)




RN 269055-15-4 CAPLUS

CN Benzonitrile, 4-[[6-amino-5-bromo-2-[(4-cyanophenyl)amino]-4-pyrimidinyl]oxy]-3,5-dimethyl- (9CI) (CA INDEX NAME)




RN 269055-18-7 CAPLUS

CN Benzonitrile, 4-[[5-bromo-2-[(4-cyanophenyl)amino]-6-(ethylamino)-4-pyrimidinyl]oxy]-3,5-dimethyl- (9CI) (CA INDEX NAME)




V. Balasubramanian


RN 269055-19-8 CAPLUS  
CN Benzonitrile, 4-[[6-amino-5-chloro-2-[(4-cyanophenyl)amino]-4-pyrimidinyl]oxy]-3,5-dimethyl- (9CI) (CA INDEX NAME)




RN 269055-26-7 CAPLUS  
CN Benzonitrile, 4-[[5,6-dichloro-2-[(4-cyanophenyl)amino]-4-pyrimidinyl]oxy]-3,5-dimethyl- (9CI) (CA INDEX NAME)




RN 269055-28-9 CAPLUS  
CN Benzonitrile, 4-[[6-bromo-5-chloro-2-[(4-cyanophenyl)amino]-4-pyrimidinyl]oxy]-3,5-dimethyl- (9CI) (CA INDEX NAME)




RN 269055-32-5 CAPLUS  
CN Acetamide, N-[5-bromo-4-(4-cyano-2,6-dimethylphenoxy)-2-pyrimidinyl]-N-(4-cyanophenyl)- (9CI) (CA INDEX NAME)



RN 269055-44-9 CAPLUS  
CN Benzonitrile, 4-[(5-bromo-2-[(4-cyanophenyl)amino]-6-methyl-4-pyrimidinyl)oxy]-3,5-dimethyl- (9CI) (CA INDEX NAME)




RN 269055-48-3 CAPLUS  
CN Benzonitrile, 4-[(5-bromo-2-[(4-cyanophenyl)amino]-6-[(2-(1-pyrrolidinyl)ethyl]amino]-4-pyrimidinyl)oxy]-3,5-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 269055-49-4 CAPLUS

CN Benzonitrile, 4-[5-bromo-2-[(4-cyanophenyl)amino]-6-(methoxyamino)-4-pyrimidinyl]oxy]-3,5-dimethyl- (9CI) (CA INDEX NAME)




RN 269055-50-7 CAPLUS

CN Acetamide, N-[4-(4-cyano-2,6-dimethylphenoxy)-2-[(4-cyanophenyl)amino]-5-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 269055-58-5 CAPLUS

CN Glycine, N-[5-bromo-4-(4-cyano-2,6-dimethylphenoxy)-2-pyrimidinyl]-N-(4-cyanophenyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 269055-59-6 CAPLUS

CN Formamide, N-[5-bromo-4-(4-cyano-2,6-dimethylphenoxy)-2-pyrimidinyl]-N-(4-cyanophenyl)- (9CI) (CA INDEX NAME)




RN 269055-60-9 CAPLUS

CN Carbamic acid, [5-bromo-4-(4-cyano-2,6-dimethylphenoxy)-2-pyrimidinyl](4-cyanophenyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 269055-61-0 CAPLUS

CN Glycine, N-[5-bromo-4-(4-cyano-2,6-dimethylphenoxy)-2-pyrimidinyl]-N-(4-cyanophenyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 269055-62-1 CAPLUS

CN Propanoic acid, 2,2-dimethyl-, [[5-bromo-4-(4-cyano-2,6-dimethylphenoxy)-2-pyrimidinyl](4-cyanophenyl)amino]methyl ester (9CI) (CA INDEX NAME)




RN 269055-63-2 CAPLUS

CN Acetic acid, [2-[[5-bromo-4-(4-cyano-2,6-dimethylphenoxy)-2-pyrimidinyl](4-cyanophenyl)amino]-2-oxoethoxy]-, methyl ester (9CI) (CA INDEX NAME)




RN 269055-78-9 CAPLUS

CN Benzonitrile, 4-[[5-amino-6-chloro-2-[(4-cyanophenyl)amino]-4-pyrimidinyl]oxy]-3,5-dimethyl- (9CI) (CA INDEX NAME)



RN 269055-79-0 CAPLUS

CN Benzonitrile, 4-[[5-amino-6-bromo-2-[(4-cyanophenyl)amino]-4-pyrimidinyl]oxy]-3,5-dimethyl- (9CI) (CA INDEX NAME)



IT 269055-76-7


RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of arylaminopyrimidines as inhibitors of HIV replication)

V. Balasubramanian

RN 269055-76-7 CAPLUS

CN Benzonitrile, 4-[[5-bromo-6-chloro-2-[(4-cyanophenyl)amino]-4-pyrimidinyl]oxy]-3,5-dimethyl- (9CI) (CA INDEX NAME)




RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

V. Balasubramanian

L5 ANSWER 22 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN  
 AN 1999:640840 CAPLUS  
 DN 131:257576  
 TI Preparation of HIV inhibiting pyrimidine derivatives  
 IN Andries, Koenraad Jozef Lodewijk Marcel; De Corte, Bart; De Jonge, Marc  
     Rene; Heeres, Jan; Ho, Chih Yung; Janssen, Marcel August Constant;  
     Janssen, Paul Adriaan Jan; Koymans, Lucien Maria Henricus; Kukla, Michael  
     Joseph; Ludovici, Donald William; Van Aken, Koen Jeanne Alfons  
 PA Janssen Pharmaceutica N.V., Belg.; et al.  
 SO PCT Int. Appl., 52 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9950250	A1	19991007	WO 1999-EP2043	19990324
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	EP 945442	A1	19990929	EP 1998-201587	19980514
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	CA 2324919	AA	19991007	CA 1999-2324919	19990324
	AU 9935996	A1	19991018	AU 1999-35996	19990324
	AU 751573	B2	20020822		
	BR 9909191	A	20001205	BR 1999-9191	19990324
	EE 200000532	A	20020215	EE 2000-532	19990324
	JP 3507917	B2	20040315	JP 2000-541155	19990324
	BG 104738	A	20010430	BG 2000-104738	20000830
	HR 2000000620	A1	20010630	HR 2000-620	20000919
	NO 2000004810	A	20000926	NO 2000-4810	20000926
PRAI	US 1998-79632P	P	19980327		
	EP 1998-201587	A	19980514		
	EP 1998-203948	A	19981125		
	WO 1999-EP2043	W	19990324		
OS	MARPAT	131:257576			
IT	<b>244767-99-5P</b>				
	RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of HIV inhibiting pyrimidine derivs.)				
RN	244767-99-5	CAPLUS			
CN	Benzonitrile, 4-[[2-[(4-cyanophenyl)amino]-4-pyrimidinyl]oxy]-3,5-dimethyl-(9CI)	(CA INDEX NAME)			

V. Balasubramanian




RE.CNT 8

THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

V. Balasubramanian

L5 ANSWER 23 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN  
AN 1999:631415 CAPLUS  
DN 131:257575  
TI Preparation of arylaminopyrimidines for treatment of human immunodeficiency virus infection.  
IN Andries, Koenraad Jozef Lodewijk Marcel; De Corte, Bart; De Jonge, Marc Rene; Heeres, Jan; Ho, Chih Yung; Janssen, Marcel August Constant; Janssen, Paul Adriaan Jan; Koymans, Lucien Maria Henricus; Kukla, Michael Joseph; Ludovici, Donald William; Van Aken, Koen Jeanne Alfons  
PA Janssen Pharmaceutica N.V., Belg.  
SO Eur. Pat. Appl., 38 pp.  
CODEN: EPXXDW  
DT Patent  
LA English  
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 945443	A1	19990929	EP 1999-200918	19990324
	EP 945443	B1	20030212		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	EP 945442	A1	19990929	EP 1998-201587	19980514
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
EP 1245567	A1	20021002	EP 2002-14566	19990324	
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL					
PRAI	US 1998-79632P	P	19980327		
	EP 1998-201587	A	19980514		
	EP 1998-203948	A	19981125		
	EP 1999-200918	A3	19990324		
OS	MARPAT	131:257575			
IT	<b>244767-99-5P</b>				
	RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of arylaminopyrimidines for treatment of HIV infection)				
RN	244767-99-5	CAPLUS			
CN	Benzonitrile, 4-[[2-[(4-cyanophenyl)amino]-4-pyrimidinyl]oxy]-3,5-dimethyl-				
	(9CI) (CA INDEX NAME)				



V. Balasubramanian

RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

V. Balasubramanian

=> log y		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
FULL ESTIMATED COST	ENTRY	SESSION
	79.43	235.06

STN INTERNATIONAL LOGOFF AT 14:22:16 ON 17 AUG 2004

10/634,682